11/20/2009 - Pfizer (NYSE:PFE) announced that the FDA approved its Revatio Injection. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulations, according to the company. It is used for the treatment of adults that have pulmonary arterial hypertension in order to improve exercise ability and delay clinical worsening. Vice president of pulmonary vascular disease, clinical development and medical affairs for Pfizer, Dr. Cara Cassino, said, "The approval of Revatio Injection is a clear demonstration of Pfizer's commitment to developing treatments addressing the unmet needs of patients with pulmonary arterial hypertension. This important milestone highlights the Specialty Care business unit's dedication to advancing treatments for serious and life-threatening conditions such as pulmonary vascular disease."

Contact Chip Brian

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at www.TradeTheTrend.com/signup.html